Product Description
Binimetinib is used in combination with encorafenib to treat melanoma (skin cancer) that has spread or cannot be removed by surgery. It is only used if the melanoma cells have the BRAF V600E or V600K mutations. Binimetinib belongs to the group of medicines, called antineoplastics (cancer medicines). (Sourced from: https://www.mayoclinic.org/drugs-supplements/binimetinib-oral-route/side-effects/drg-20443876?p=1)
Mechanisms of Action: MAP2K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Arab Emirates | United Kingdom | United States
Approved Indications: Melanoma
Known Adverse Events: Abdominal Pain | Pain Unspecified | Diarrhea
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 54
Highest Development Phases
Phase 3: Biliary Tract Cancer|Colorectal Cancer|Fallopian Tube Cancer|Melanoma|Ovarian Cancer
Phase 2: Brain Cancer|Breast Cancer|Glioma|Multiple Myeloma|Neurofibroma, Plexiform|Neurofibromatoses|Neurofibromatosis 1|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Oncology Unspecified|Pancreatic Cancer|Thyroid Cancer|Triple Negative Breast Cancer|Uveal Melanoma
Phase 1: Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2021-004310-19 | P3 |
Active, not recruiting |
Melanoma |
2035-04-19 |
|
| 2021-000743-41 | P3 |
Active, not recruiting |
Melanoma |
2035-01-21 |
|
| The STARBOARD Study | P3 |
Active, not recruiting |
Melanoma |
2030-06-29 |
|
| BEPCOME-MB | P2 |
Active, not recruiting |
Melanoma |
2030-01-13 |